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Genetic Association with ERAP1 in Psoriasis Is
Confined to Disease Onset after Puberty and
Not Dependent on HLA-C*06
Josefin Lysell1, Leonid Padyukov2, Ingrid Kockum3, Pernilla Nikamo1 and Mona Sta˚hle1
HLA-C remains the strongest susceptibility candidate gene in psoriasis. Evidence for interaction between HLA-C
and endoplasmic reticulum aminopeptidase 1 (ERAP1) confined to individuals carrying the HLA-C risk allele was
recently reported. Psoriasis displays wide variation, and genetic heterogeneity is likely to contribute to clinical
diversity. Age at disease onset is a putative discriminator, and separating psoriasis into early- (o40 years) and
late-onset disease has been useful. To sharpen the age-dependent phenotype, we compared genotypes for
ERAP1 (rs26653, rs30187, and rs27524) and HLA-C*06:02 in healthy controls and cases stratified for onset of
psoriasis at o10, 10–20, 20–40, and 440 years of age. This approach revealed that association with ERAP1 was
confined to cases with onset between 10 and 20 years (odds ratio 1.59, 95% confidence interval: 1.28–1.98,
P¼ 0.00008) and no association was detected in cases with onset below 10 years, reflecting genetic
heterogeneity within the childhood psoriasis population. In contrast to earlier findings, association with ERAP1
was neither dependent on nor interacting with HLA-C*06:02. ERAP1 single-nucleotide polymorphism rs26653,
which, to our knowledge, has not previously been reported in psoriasis, is nonsynonymous, has suggestive
functional consequences, and herein displays strong association with disease.
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INTRODUCTION
Psoriasis is a highly heterogeneous disease with a complex
genetic background, and the strategy to stratify into sub-
groups is likely to be fruitful for fully understanding the
spectrum of the disease. The underlying genetics may affect
the age at onset, and separating psoriasis into early- and
late-onset disease using 40 years as the divider has been
useful (Henseler and Christophers, 1985). Using this defini-
tion, early-onset psoriasis has been shown to have a higher
degree of heritability and a higher prevalence of HLA-
C*06:02 (Henseler and Christophers, 1985; Gudjonsson
et al., 2006). However, onset before the age of 40 years has
been reported in B75% of patients with psoriasis and thus
this definition of early-onset comprises the majority of
patients with psoriasis (Zhang et al., 2002). Nevertheless,
most genetic studies use this classification and lack a more
detailed stratification.
Other stratification attempts separate patients according to
HLA-C status. Presence of the risk allele HLA-C*06:02 is
claimed to be associated with earlier disease onset, more
severe disease course, and a higher prevalence of the guttate
phenotype (Mallon et al., 2000; Gudjonsson et al., 2006). Nail
and joint manifestations are reported to be more frequent in
HLA-C*06:02-negative patients (Gudjonsson et al., 2006).
Onset of psoriasis in adolescence and early adulthood is
common, and a potential impact of puberty has been
discussed (Braun-Falco et al., 1972; Farber and Nall, 1974;
Swanbeck et al., 1995; Raychaudhuri and Gross, 2000).
However, before puberty the onset of psoriasis is more unusual
and is estimated to occur in only 10% of patients before the
age of 10 and in 2% before the age of 2 years (Farber and Nall,
1974; Farber and Jacobs, 1977). Children with psoriasis may
differ in their clinical presentation compared with adults and a
correct diagnosis may be delayed, which is a potential
confounder when determining disease onset in this group
(Morris et al., 2001; de Jager et al., 2010).
HLA-C*06:02 is the candidate gene allele with the
strongest association with psoriasis (Elder, 2006; Fan et al.,
2008). Exactly how HLA-C*06:02 contributes to disease is,
however, still unclear. A recent genome-wide association
study reported evidence for a genetic interaction between
the HLA-C and endoplasmic reticulum aminopeptidase 1
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(ERAP1) genes (combined P¼ 6.95106), with the ERAP1-
associated synonymous single-nucleotide polymorphism
(SNP) (rs27524) affecting psoriasis susceptibility only in
individuals carrying the HLA-C risk allele (Strange et al.,
2010). ERAP1 has an important role in MHC class I peptide
processing in the endoplasmic reticulum and has also been
shown to be involved in shedding of proinflammatory
cytokine receptors, altogether suggestive of a potential
involvement in the pathogenesis of psoriasis (Cui et al.,
2003a; Hearn et al., 2009; Haroon and Inman, 2010). Other
nonsynonymous ERAP1 SNPs have been shown to be
associated with ankylosing spondylitis (rs30187, rs26653)
and multiple sclerosis (rs30187) (Burton et al., 2007; Reveille,
2011; Guerini et al., 2012). Altogether, these data suggest
that ERAP1 may be essential in regulating immunity.
Herein we present a cohort of psoriasis patients stratified
for phenotype (plaque and guttate) and age at onset (Table 1).
The age groups were chosen in an attempt to reflect
biologically significant transitions. In particular, we aimed
to explore the impact of puberty. Setting the limit for puberty
at 10 years represents a stringent approach (Parent et al.,
2003). Herein we report a strong association of ERAP1 SNP
rs26653 not restricted to HLA-C*06:02-positive individuals.
Stratification for age at onset revealed that ERAP1 association
was confined to cases with disease onset between 10 and 20
years (odds ratio (OR) 1.59, 95% confidence interval (CI):
1.28–1.98, P¼0.00008), whereas prepubertal children with
onset between 0 and 9 years lacked association (OR 1.24,
95% CI: 0.93–1.65, P¼0.4). This work reveals striking
genetic heterogeneity among patients with early-onset
psoriasis and stresses the importance of detailed stratification
in future genetic studies in psoriasis.
RESULTS
The association of HLA-C*06:02 varies with the age at disease
onset in psoriasis
The established and strong association of HLA-C*06:02 with
psoriasis was confirmed in our cases (OR 4.51, 95% CI:
3.81–5.3, P¼4.9 1076) (Table 2). For analysis of a possible
effect of age at onset, we separated the cases into four groups
(Table 1). The strongest association for HLA-C*06:02 was
detected in the age group 10–20 years (OR 8.46, 95% CI:
6.65–10.77, P¼1.3 1086), which was significantly stron-
ger than that in the groups 0–9 (OR 5.71, 95% CI: 4.19–7.79,
P¼1.21033) and 21–40 (OR 5.52, 95% CI: 4.40–6.92,
P¼8.91058) (Table 3). In the oldest group with
onset of disease above 40 years, the association with HLA-
C*06:02 was significant, albeit much lower (OR 1.89,
95% CI: 1.45–2.46, P¼9.1 106) than published data
(Allen et al., 2005). The distribution of plaque and guttate
Table 1. Characteristics of participants
Age at onset
0–9 (N=119) 10–20 (N=203) 21–40 (N=283) 440 (N=349) All (N=954) Controls (N=1,748)
Women (%) 58 (49) 112 (55) 137 (48) 216 (62) 523 (55) 1,026 (59)
Mean age at onset 5.4 14.9 31.0 56.8 33.9
Plaque phenotype (%) 96 (81) 157 (77) 201 (71) 309 (89) 763 (80)
Plaque phenotype HLA-Cw06 (%) 44 (46) 104 (66) 84 (42) 55 (17) 287 (38)
Guttate phenotype (%) 23 (19) 46 (23) 82 (29) 40 (11) 191 (20)
Guttate phenotype HLA-Cw06 (%) 19 (83) 38 (83) 69 (84) 25 (57) 151 (79)
Abbreviation: N, number of subjects.
Table 2. Markers analyzed in ERAP1 and HLA-C*06 as well as allelic associations
MAF All cases
Chr Gene Marker Region1 Variation2 Alleles3 Controls Cases P4 OR (95% CI)
5 ERAP1 rs26653 Exon 2 Arg127Pro C/G 0.26 0.31 0.00006 1.31 (1.16–1.48)
5 ERAP1 rs30187 Exon 11 Lys528Arg T/C 0.34 0.38 0.02 1.16 (1.03–1.30)
5 ERAP1 rs27524 30 UTR None A/G 0.36 0.39 0.11 1.10 (0.98–1.23)
6 HLA-C rs10484554 None coding None T/C 0.10 0.28 1.8 1065 3.55 (3.06–4.13)
6 HLA-C Cw06:025 P/N 0.07 0.24 4.9 1076 4.51 (3.81–5.34)
Abbreviations: CI, confidence interval; ERAP, endoplasmic reticulum aminopeptidase 1; MAF, minor allele frequency; OR, odds ratio; UTR, untranslated region.
1Data from www.ensembl.org.
2Data from www.ncbi.nlm.nih.gov.
3Minor allele/major allele.
4Adjusted P-value for five tests with Holm as implemented in PLINK adjust.
5See Nikamo and Stahle (2012).
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phenotypes was similar in the three younger age cohorts but
more skewed toward plaque phenotype in the oldest group
(Table 1).
Replication of association for ERAP1 in psoriasis
The association of ERAP1 in psoriasis was reported recently
(Strange et al., 2010; Bergboer et al., 2012). We investigated
three SNPs in the ERAP1 gene (Table 2). Significant allelic
association was found for rs26653 (OR 1.31, 95% CI:
1.16–1.48, P¼ 0.00006) and rs30187 (OR 1.16, 95% CI:
1.03–1.30, P¼0.02) in the total data set. No association
was found for rs27524 (OR 1.10, 95% CI: 0.98–1.23,
P¼0.11) in the total data set (Table 2), although we did find
association with rs27524 in the group with disease onset
between 10 and 20 years (OR 1.28, 95% CI: 1.04–1.58,
P¼0.02) (Table 3).
Association with ERAP1 is not dependent on HLA-C*06:02 and
is confined to cases with disease onset between 10 and 20 years
In contrast to previous findings, in which the association of
ERAP1 rs27524 was confined to individuals carrying the
HLA-C*06:02 allele, the association with rs26653 was
independent of HLA-C*06:02 in the total data set
(P¼0.001, OR 1.39 95% CI: 1.14–1.70) (Table 4a). Associa-
tion independent of HLA-C*06:02 with rs27524 and rs30187
was found only in the group with onset between 10 and
20 years (Table 4b). No interaction between ERAP1 (rs26653,
rs30187, rs27524) and HLA-C*06:02 was detected, neither in
the total data set (Supplementary Table S1 online) nor in the
significantly associated group with onset between 10 and 20
years (data not shown).
Stratification for age at onset as described above showed
association for all three nonsynonymous ERAP1 SNPs
rs26653 (OR 1.59, 95% CI: 1.28–1.98, P¼ 0.00008),
rs30187 (OR 1.46, 95% CI: 1.18–1.80, P¼ 0.0001), and
rs27524 (OR 1.28, 95% CI: 1.04–1.58, P¼ 0.02) in the
group of patients with onset between 10 and 20 years.
The association with ERAP1 in the 10–20 age group
was significantly stronger compared with all other age
groups (rs26653; OR 1.28 95% CI: 1.01–1.62, P¼0.04,
rs30187; OR 1.30, 95% CI: 1.03–1.63, P¼ 0.03). In the
group with age at onset between 21 and 40 years, there was
Table 3. Allelic associations for ERAP1 and HLA-C genes in psoriasis patients stratified for age at onset (case versus
controls)
Age at onset
Age 0–9 Age 10–20 Age 21–40 Age 440
Marker MAF ca P1 OR (95% CI) MAF ca P1 OR (95% CI) MAF ca P1 OR (95% CI) MAF ca P1 OR (95% CI)
rs26653 0.30 0.4 1.24 (0.93–1.65) 0.36 0.00008 1.59 (1.28–1.98) 0.31 0.05 1.27 (1.05–1.54) 0.30 0.1 1.21 (1.01–1.44)
rs30187 0.39 0.4 1.20 (0.91–1.57) 0.43 0.0001 1.46 (1.18–1.80) 0.35 1 1.03 (0.85–1.24) 0.37 0.5 1.11 (0.93–1.31)
rs27524 0.39 0.4 1.12 (0.86–1.47) 0.42 0.02 1.28 (1.04–1.58) 0.36 1 0.98 (0.81–1.18) 0.38 0.5 1.09 (0.92–1.29)
rs10484554 0.33 2.5 1028 4.66 (3.48–6.24) 0.42 2.9 1072 6.65 (5.29–8.35) 0.31 4.6 1046 4.25 (3.44–5.24) 0.15 0.0005 1.59 (1.25–2.02)
HLA-Cw06:02 0.29 1.2 1033 5.71 (4.19–7.79) 0.38 1.3 1086 8.46 (6.65–10.77) 0.28 8.9 1058 5.52 (4.40–6.92) 0.12 9.1 106 1.89 (1.45–2.46)
Abbreviations: CI, confidence interval; ERAP, endoplasmic reticulum aminopeptidase 1; MAF ca, minor allele frequency cases; OR, odds ratio.
1Adjusted P-value for five tests with Holm as implemented in PLINK adjust.
Table 4a. Independent association of ERAP1 SNP
rs26653 and HLA-C*06 in all subjects
rs26653 HLA-C*06 P-value OR (95% CI)
GG NN 1 1
GC/CC NN 0.001 1.39 (1.14–1.70)
GG P o21016 6.21 (4.73–8.14)
GC/CC P o21016 7.17 (5.47–9.39)
Abbreviations: CI, confidence interval; ERAP, endoplasmic reticulum
aminopeptidase 1; NN, negative for HLA-C*06; OR, odds ratio; P, positive
for HLA-C*06; SNP, single-nucleotide polymorphism.
Generalized linear model as implemented in R software package.
Individuals with the low risk genotype for rs26653 and HLA-C*06 NN
were set as baseline.
Table 4b. Independent association of ERAP1 SNPs and
HLA-C*06 in the age group 10–20
ERAP1
SNP
ERAP1
genotype HLA-C*06 P-value OR (95% CI)
rs26653 GG NN 1 1
GC/CC NN 0.009 2.02 (1.19–3.43)
GG P o21016 19.43 (11.55–32.66)
GC/CC P o21016 27.11 (16.35–44.95)
rs30187 CC NN 1 1
TC/TT NN 0.0005 3.10 (1.64–5.87)
CC P o21016 28.00 (14.26–54.96)
TC/TT P o21016 38.70 (20.63–72.58)
rs27524 GG NN 1 1
GA/AA NN 0.002 2.68 (1.41–5.08)
GG P o21016 30.10 (15.43–58.70)
GA/AA P o21016 33.96 (18.09–63.76)
Abbreviations: CI, confidence interval; ERAP, endoplasmic reticulum
aminopeptidase 1; NN, negative for HLA-C*06; OR, odds ratio; P, positive
for HLA-C*06; SNP, single-nucleotide polymorphism.
Generalized linear model as implemented in R software package.
Individuals with risk alleles for respective ERAP1 SNPs and HLA-C*06.
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borderline association for rs26653 (OR 1.27, 95% CI:
1.05–1.54, P¼ 0.05).
No significant difference in ERAP1 association was found
when we stratified for the clinical phenotypes, plaque or
guttate (Supplementary Figure S1 online).
DISCUSSION
The present view within the field of psoriasis is that the earlier
the onset of disease, the stronger the association with HLA-
C*06:02 and the more severe the disease (Gudjonsson et al.,
2006). The data presented herein reveal a more complex
scenario where patients with onset of psoriasis during
adolescence (here 10–20 years) emerge as a distinct group
compared with those with onset before puberty (Figure 1).
Children with disease onset below the age of 10 years have a
prevalence of HLA-C*06:02 similar to that of patients with
adult onset (21–40 years) and lack association with ERAP1,
whereas cases with onset of disease between 10 and 20 years
have a significantly higher prevalence of HLA-C*06:02
irrespective of phenotype and also show a significant
association with ERAP1 (Table 3). These data indicate an
age-dependent difference in the genetic background among
patients with early onset of psoriasis. Keeping in mind the
limited number of cases in each group, we believe that the
stringent inclusion criteria and careful phenotyping by only a
handful of dermatologists around the time of disease onset
serve to reinforce the results. Whether these genetic
differences will translate into clinical differences in terms of
disease development, severity, and comorbidity profiles
should be explored in future studies.
Obviously, any stratification involves simplification, but
we believe that a cutoff at 10 years of age represents a valid
approximation for puberty that constitutes a significant
biological transition (Parent et al., 2003). In patients with
juvenile psoriatic arthritis a similar pattern of two distinct
populations of early-onset disease was presented, one with a
peak of onset around the age of 2–3 years and the other group
with a peak of onset around 10–12 years. Genetic and clinical
differences were detected between these groups of juvenile
psoriatic arthritis patients (Stoll et al., 2006; Stoll and Punaro,
2011). An additional study on juvenile arthritis showed
subtype-specific association with ERAP1 and IL23R, in which
the enthesitis-related arthritis subtype associated with ERAP1,
whereas juvenile psoriatic arthritis showed association with
IL23R (Hinks et al., 2011). A recent study in a small group of
childhood psoriasis patients, separating early and late onset
at 18 years of age, showed results in accordance with the data
presented herein, with a stronger association with ERAP1
rs27524 in the group with onset of disease before 18 years
(Bergboer et al., 2012).
A peak of disease onset at puberty has been shown in
cases of psoriasis, which is slightly earlier in girls than in boys
(Swanbeck et al., 1995). The mechanisms underlying this
increase are not known today. A possible effect of increased
levels of sex hormones at puberty, in particular estrogens,
which are known to promote keratinocyte proliferation via
receptor-mediated mechanisms and also to influence inflam-
matory pathways, has been discussed (Moverare et al., 2002;
Kanda and Watanabe, 2005). Other potential triggers may be
different infectious panorama in different age groups.
The distribution of phenotypes in the present study reveals
a relatively high proportion of the guttate subtype. This may
in part be explained by the recruitment strategy, which has
been described in detail (Mallbris et al., 2005). In short,
patients were recruited in association with onset of first
psoriasis episode and the diagnosis verified by a trained
dermatologist in a single center. In the majority of patients
(77%) an associated streptococcal infection was confirmed.
Earlier studies have shown a higher prevalence of HLA-
C*06:02 in patients with guttate psoriasis (Mallon et al.,
2000; Gudjonsson et al., 2006). The distribution between
phenotypes (plaque versus guttate) in prepubertal and
postpubertal children was similar in our study (Table 1).
Thus, differences in HLA-C*06:02 prevalence between
prepubertal children and postpubertal children cannot be
attributed to a higher percentage of the guttate phenotype in
the latter group but was rather contributed by a larger
percentage of plaque cases carrying HLA-C*06:02 in the
10–20-year age group.
As expected, cases with late onset of disease (above 40
years) had significantly lower association with HLA-C*06:02
and also lacked association with ERAP1, confirming that 40
years represents a biologically valid approximation for a
genetically distinct subgroup of psoriasis.
This work replicates the association of ERAP1 in psoriasis.
We studied three SNPs in the ERAP1 gene (Table 2). The
SNPs rs26653 (Arg127Pro) and rs30187 (Arg528Lys) have
been shown to be associated with ankylosing spondylitis
(rs26653 and rs30187) and multiple sclerosis (rs30187) and
showed association with psoriasis in the present study
(Harvey et al., 2009; Maksymowych et al., 2009; Reveille,
2011; Guerini et al., 2012). In contrast to the previously
reported synonymous SNP rs27524, these latter SNPs are
nonsynonymous and have been shown to be functional,
affecting the catalytic activity of the enzyme (Goto et al.,
2006; Mehta et al., 2009; Evnouchidou et al., 2011). The lack
of association with the synonymous ERAP1 SNP rs27524 in
our data set could be because of two reasons: (a) our
associated group (age 10–20) comprises only 21% of our total
100%
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Figure 1. HLA-C*06:02 carrier and noncarrier distribution in the whole
sample set. Frequency of HLAC*06:02 allele in the different age-at-onset
groups.
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cases, which may not be sufficient to reach significance. If we
randomly reduce the number of cases in the other age groups
so that the 10–20-year group would make up 36% of the total
data set, comparable to data recently presented in Bergboer
et al. (2012), the association with rs27524 would be
significant in our study as well (Bergboer et al., 2012). (b)
There are too few individuals carrying two minor alleles as
rs27524 follows a recessive model, meaning that two minor
alleles are needed for risk (Supplementary Table S2 online).
The SNPs rs26653 and rs30187 on the other hand display an
additive genotypic effect (Supplementary Table S2 online).
The finding of significant association with rs30187 strength-
ens this conclusion, as rs30187 and rs27524 are in linkage
disequilibrium.
Thus, stratification for age at onset revealed a clear age-
dependent association with ERAP1 (Table 3). Surprisingly, in
our cases, association with ERAP1 was not restricted to
individuals carrying HLA-C*06:02, and patients negative for
HLA-C*06:02 with the rs26653 minor allele show an OR of
1.39 (95% CI: 1.14–1.70, P=0.001) (Table 4a). The additive
effect of carrying the minor allele (C) for rs26653 in HLA-
C*06:02-positive patients was seen between GG/P and GC/P
genotype groups (Figure 2). Calculations for additive interac-
tion and multiplicative interaction with stratification for
different phenotypic and genetic data did not reveal any
interactions. At present, we cannot explain the discrepancy
between our findings and published data on ERAP1 associa-
tion being dependent on HLA-C*06:02 (Strange et al., 2010).
In the latter publication, the authors applied typing of
rs10484554 to determine HLA-C status, which is different
from the present method, which captures only HLA-C*06
genotypes (Nikamo and Stahle, 2012). However, using
rs10484554 in our study did not alter the results (not shown).
At present, the functional consequences of ERAP1 poly-
morphisms in psoriasis are unknown. ERAP1 has several
functions. It may act as a ‘‘molecular ruler’’ clipping peptides
for optimal HLA class I binding and presentation (Saric et al.,
2002; Chang et al., 2005). Second, in vitro studies suggest
that ERAP1 cleaves cytokine receptors off the cell surface,
including tumor necrosis factor receptor I (Cui et al., 2002),
IL-1R2 (Cui et al., 2003b), and IL6Ra (Cui et al., 2003a).
However, a recent study showed that the ERAP1 polymorph-
isms associated with ankylosing spondylitis did not influence
the serum cytokine receptor levels in patients with ankylosing
spondylitis (Haroon et al., 2010). The peptide-trimming
function theoretically implies a biological interaction with
HLA and has so far been thought to be causative for most of
the effect in psoriasis. However, functional studies are
lacking, and the importance of a ‘‘sheddase’’ function for
ERAP1 in psoriasis and other inflammatory needs further
exploration.
To investigate whether clinical subtype (plaque or guttate)
influenced association with ERAP1, we stratified for pheno-
type. No significant difference was detected (Supplementary
Figure S1 online).
In summary, we found that childhood psoriasis is a
genetically heterogeneous group with significant differences
between prepubertal and postpubertal disease onset. Pre-
pubertal cases had a similar profile for HLA-C and ERAP1 as
the group with onset between 21 and 40 years, whereas the
group with onset between 10 and 20 years emerges as a
distinct cluster carrying the strongest genetic HLA-C and
ERAP1 association. In contrast to previous reports, the
association with ERAP1 (rs26653) was neither dependent
on nor interacting with HLA-C*06:02. Our work stresses the
importance of detailed stratification for age at disease onset in
further genetic and mechanistic studies in psoriasis. We do
acknowledge the importance of replicating the present
findings in a separate cohort of psoriasis patients. It will then
be crucial to use a stringent clinical classification of the
psoriasis diagnosis, which may be particularly difficult in
children. In addition, reliable data on age at onset must be
secured to avoid dilution of data.
MATERIALS AND METHODS
Study population
All patients included in the study were examined and the diagnosis
of psoriasis verified by dermatologists at the department of
Dermatology, Karolinska University Hospital, Stockholm, Sweden.
The study was approved by the Regional Committee of Ethics and
conducted according to the Declaration of Helsinki Principles.
Patients and controls gave their informed consent; for children
younger than 18 years of age, consent was also obtained from their
parents. For inclusion, patients needed to present with at least one
typical psoriasis lesion at the time of examination. Scalp involve-
ment and/or diaper rash alone was not regarded as diagnostic. Only
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Figure 2. Association for ERAP1 SNP rs26653 stratified for HLA-Cw06 status
and age. Estimates of genotype effects were calculated using logistic
regression in the R software package. Individuals with the low-risk genotypes
for rs26653 GG and HLA-C*06 NN were set as the baseline. The other
genotype combinations were coded according to a series of dichotomous
indicator variables. Odds ratios were derived by exponentiation of the
relevant coefficient from the logistic regression.
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patients categorized as having plaque or guttate psoriasis were
enrolled in the study to minimize clinical heterogeneity (Table 1).
Other more rare phenotypes were excluded. Disease severity ranged
from mild to severe psoriasis, representing a cross-section of
psoriasis patients. Healthy controls were recruited from the
Dermatology (n¼ 513) clinic at the Karolinska University Hospital
and from the Epidemiological Investigation of Rheumatoid arthritis
study (EIRA study) (n¼ 1235) (Stolt et al., 2003). Only cases and
controls of Caucasian origin based on ethnicity SNP genotyping
were included (Giardina et al., 2008). Controls were matched for sex
(59% female/41% male).
Genotyping
Peripheral blood samples were collected and genomic DNA
extracted by standard procedures. SNPs were selected on the basis
of previous publications (Haroon and Inman, 2010; Strange et al.,
2010; Szczypiorska et al., 2011). All SNPs were genotyped on a
7900HT Fast Real-Time PCR System Instrument by using allele-
specific Taqman MGB probes labeled with fluorescent dyes FAM
and VIC (Applied Biosystems), according to the manufacturer’s
protocols. Allelic discrimination was made with the ABI PRISM
7900HT SDS and the SDS 2.2.1 program (Applied Biosystems). Ten
percent of the samples were run as duplicates to check for
genotyping errors. HLA-C*06:02 typing was carried out as described
and referred to as positive when the HLA-C*06:02 allele was present
and negative when not present (Nikamo and Stahle, 2012). We
studied three SNPs in the ERAP1 gene, rs26653 (Arg127Pro),
rs30187 (Lys528Arg), and rs27524 (UTR30). rs27524 and rs30187
were in linkage disequilibrium (r2¼ 0.75).
Statistical analysis
Case–control analysis was performed to test genetic markers for
susceptibility to psoriasis. Case–case analysis was used to compare
frequencies of genetic markers in plaque and guttate phenotypes and
for different age groups. Both case–control and case–case analyses
were tested for allele frequency differences for the three ERAP1 SNPs
(rs26653 (Arg127Pro), rs30187 (Lys528Arg), and rs27524 (UTR30))
and for the HLA-C genotype using logistic regression. Association
between genetic markers and disease status was analyzed using
PLINK v1.07 (Purcell, 2007, #85). Association for ERAP1 SNP
rs26653 stratified for HLA-C*06:02 status and age, as well as
independent association for ERAP1 using patients negative for
ERAP1 and HLA-C*06:02 minor allele as the reference group, was
calculated using R v2.15.0 with GLM (http://www.r-project.org/).
We also used R v2.15.0 with GLM (http://www.r-project.org/) to test
for interaction between ERAP1 and HLA-C*06:02 using both
additive and multiplicative modes. Hardy–Weinberg equilibrium
was evaluated for each SNP using the w2-test. Significant P-values
were corrected for multiple testing using the adjust mode as
implemented in PLINK v1.07 (Purcell, 2007 #85).
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